The glucagon and GLP-1 receptor dual agonist DD01 for metabolic dysfunction-associated steatotic liver disease and steatohepatitis (DD01-DN-02): 12-week results from a randomised, double-blind, multicentre, placebo-controlled, phase 2 trial

Study limitation reported by the research below: “DD01 does not yet have a nonproprietary INN; 'DD01' is used as the investigational name throughout.”